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Inhibition of programmed cell death is considered to be amajor aspect of tumorigenesis. Indeed, several key
oncogenic transcription factors, such as NF-kB and STAT3, exert their tumor-promoting activity at least in
part through upregulation of survival genes. However, many cancers develop in response to chronic tissue
injury, in which the resulting cell death increases the tumorigenic potential of the neighboring cells. In this
review, we discuss a resolution to this paradox based on cell death-mediated induction of tumor promoting
inflammatory cytokines, which enhance cell survival and trigger compensatory proliferation in response to
tissue injury.Introduction
The idea that tissue injury and cancer are linked is not new. As far
back as 1863, Rudolf Virchow hypothesized that previous tissue
injury is required for tumor emergence (Mantovani et al., 2008).
This hypothesis has gained recent support from clinical data
revealing a strong association between chronic injury and subse-
quent tumorigenesis at the same site. For instance, alcohol
abuse causes liver injury and increased risk of hepatocellular
carcinoma (HCC). Betel nut chewing, cigarette smoking, and
exposure to fine silica dust cause esophageal and lung damage
and promote cancer development in these tissues, whereas
chronic infection with Helicobacter pylori causes gastritis and
stomach cancer (El-Serag and Rudolph, 2007; Hecht, 2002;
Uemura et al., 2001). How does tissue injury promote tumorigen-
esis? Certainly mutagenesis, genomic instability, and epigenetic
modifications are important in this relationship, but they can be
insufficient. Because of strong similarities between key features
of wound healing and tumor development, including stem cell
andmyofibroblast activation, enhanced cell proliferation, inflam-
mation, and neoangiogenesis, it is tempting to postulate that
chronic injury can result in an aberrant healing and regenerative
response that ultimately promotes the expansion and progres-
sion of initiated cells. This idea has already been forwarded by
Alexander Haddow who suggested that ‘‘tumor production is
a possible overhealing’’ (Haddow, 1972) and Harold Dvorak
who stated that ‘‘tumors are wounds that do not heal’’ (Dvorak,
1986).
Can the prevalence of inflammation be the link between tissue
injury and cancer? Recent studies have highlighted the particular
importance of inflammation in both processes. These studies
have indicated that the role of inflammation extends far beyond
protection of the injured tissue from infectious agents and
removal of damaged cells. In fact, inflammation is critical to
almost every phase of tissue repair and tumorigenesis. Thus,
we put forth that injury causes inflammation, which in turn
orchestrates wound healing and tissue regeneration. If the
inflammation cannot be resolved or is chronically provoked by
repetitive injury or other factors, the resulting unchecked wound
healing process can promote cancer formation. This hypothesisis supported by a large body of data, which is briefly summarized
below and depicted in Figure 1.
It should be noted that at least several different types of
inflammation associated with tumorigenesis can be delineated
(Grivennikov et al., 2010). Certain types of inflammation, such
as tumor elicited inflammation, defined as recruitment of
immune cells into a growing tumor, occur only in later stages
of tumor development. Such inflammation may not be depen-
dent on cell death preceding tumorigenesis and can be elicited
by chemokines secreted by the tumor (Karin, 2005), but nonethe-
less can still influence later aspects of tumor progression. Tumor
elicited inflammation may also drive metastatic progress as
recent studies of breast and prostate cancers have demon-
strated (DeNardo et al., 2009; Kim et al., 2009; Luo et al., 2007;
Tan et al., 2011). However, it is entirely plausible that necrosis,
resulting from hypoxia at the tumor core may be one type of
‘‘injury’’ signal that triggers, or at least contributes to, tumor-eli-
cited inflammation. Despite the multiple facets of cancer-linked
inflammation, this review is focused on the role of tissue injury
and cell death as drivers for the inflammation that contributes
to tumor initiation and early promotion. Other aspects of inflam-
mation in cancer have been reviewed elsewhere (Grivennikov
et al., 2010; Joyce and Pollard, 2009; Mantovani et al., 2008).
After injury, even when no infectious agents are present,
immune cells quickly migrate into the injured tissue after vasodi-
latation and in response to chemokine gradients, classically
described as the inflammatory stage of wound healing (Velnar
et al., 2009). These cells promote healing by releasing cytokines
such as tumor necrosis factor (TNF), interleukin (IL)-1, and IL-6
that suppress further cell death, activate stem cells, and promote
epithelial proliferation. For example, depletion of macrophages
during the early and middle phases of skin wound repair results
in attenuated epithelial proliferation and wound contraction
(Lucas et al., 2010). The same cytokines are expressed by
tumor-associated inflammatory cells and sometimes by cancer
cells themselves and promote cancer cell proliferation while
suppressing the death of premalignant cells (see below).
Neovascularization during wound healing is critical for providing
nutrients and oxygen to the newly remodeled tissue. AfterImmunity 35, October 28, 2011 ª2011 Elsevier Inc. 467
Figure 1. Tumorigenesis in Response to
Chronic Tissue Injury of Different Types
Tissue injury and cell death lead to activation of
various inflammatory cells that secrete cytokines
that promote wound healing. However, if this
process is reiterated several times or inflammation
fails to resolve, tissue regeneration may be dys-
regulated and, when combined with carcinogen
exposure, can lead to malignant transformation.
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macrophages and neutrophils secrete molecules such as
vascular endothelial growth factor A (VEGFA) to promote blood
vessel development and tissue remodeling (Bao et al., 2009).
In tumors, inflammatory cells play a similar role by promoting
neoangiogenesis (Lewis et al., 2000). In particular, VEGF-
secreting macrophages are critical to tumor development, given
that their depletion reduced vascular density in a breast cancer
model (Stockmann et al., 2008). Fibroblast activation or the
conversion of tissue fibroblasts into myofibroblasts, which
engage in extracellular matrix (ECM) deposition and scar forma-
tion, is critical for wound healing (Wynn, 2008). The main activa-
tors of fibroblasts after tissue injury are M2-polarized macro-
phages that are recruited to the site of injury where they
secrete factors such as platelet-derived growth factor (PDGF),
connective tissue growth factor (CTGF), and transforming
growth factor b (TGF-b). In tumorigenesis, cancer-associated
fibroblasts (CAFs) have long been thought to promote malignant
progression (Orimo and Weinberg, 2006). Although the origin of
CAF and their mode of activation remain controversial, immune
cell secretion of TGF-b may be instrumental, whereas CAF are
essentially identical in their properties to myofibroblasts, espe-
cially in their ability to produce a large number of chemokines
(Tan et al., 2011).
Not surprisingly, somatic stem cell activation is critical for
tissue repair. For example, ablation of hair follicle stem cells
leads to a complete hair loss after skin injury (Ito et al., 2005).
Furthermore, pathways critical for stem cell maintenance and
expansion, such as the Hedgehog and Wnt signaling pathways,
are also important for injury repair and tumorigenesis (Beachy
et al., 2004). Several studies have implicated inflammation in
stem cell function. For example, cytokines such as TNF and
IL-6 promote stem cell proliferation (Widera et al., 2006), and
their transcriptional effectors NF-kB and STAT3 are involved in
stem cell renewal (Matsuda et al., 1999) and cancer (Grivennikov
et al., 2010). Much emphasis has recently been placed on cancer
stem cells (CSCs), the functional homologs of somatic stem
cells that are responsible for tumor initiation and regrowth after
debulking (Lobo et al., 2007). Although still poorly explored,468 Immunity 35, October 28, 2011 ª2011 Elsevier Inc.inflammation is likely to promote CSC
maintenance and proliferation. Reactive
oxygen species (ROS), possibly origi-
nating from inflammatory cells, can
modulate self-renewal of chronic myeloid
leukemia stem cells (Miyamoto et al.,
2007). Furthermore, macrophages can
promote CSC tumorigenicity through
IL-6, STAT3, and the Hedgehog pathway
(Jinushi et al., 2011) and IL-6, STAT3, andNF-kB can convert non-stem cells to CSCs (Iliopoulos et al.,
2011). These findings lend support to the idea that cancer and
wound healing progress through similar mechanisms, many of
which are affected by inflammatory cytokines. However, an
even stronger parallel between inflammation-promoted wound
healing and cancer may be the role of inflammation in tumor
recurrence. For example, partial hepatectomy, a preferred treat-
ment for localized HCC, is initially successful, but within 5 years,
recurrence rates approach 100% (Schwartz et al., 2007).
Compensatory hepatocyte proliferation and HCC development
depend on similar mechanisms in which IL-6 and STAT3 play
key roles (He et al., 2010; Naugler et al., 2007). Similarly, the
mainstay of advanced prostate cancer treatment is androgen
deprivation therapy, which causes the death of androgen-
dependent tumor cells. However, this therapy also promotes
the recurrence of castration-resistant cancer (Gulley et al.,
2003). We recently found that lymphotoxin (LT), a TNF family
member expressed by tumor infiltrating B cells, plays a key
role in this process (Ammirante et al., 2010). Thus, therapy-
induced inflammation is likely to contribute to tumor recurrence,
although it was also proposed to enhance therapeutic outcomes
in other cases (Zitvogel et al., 2010).
In summary, although the complete details of the interconnec-
tion between injury, inflammation, and cancer are still being
unraveled, there is substantial evidence that inflammation is
essential in both tissue repair and cancer. In both cases, certain
forms of cell death promote inflammation and inflammatory
cytokines enhance tissue repair and tumorigenesis, in part, by
suppressing the death of remaining neoplastic cells.
Inflammatory versus Noninflammatory Cell Death
The mechanisms by which tissue injury triggers inflammation
are complex and not fully understood. Among initial triggers of
injury-induced inflammation, necrotic cell death is of particular
importance. However, the early distinction between necrotic
cell death being inflammatory and apoptosis being an anti-
inflammatory form of cell death has become somewhat diffuse.
Below, we briefly review mechanisms that link local injury and
cell death to induction of inflammation and cytokine production
Figure 2. Cell Death and Inflammation
Whereas normal apoptotic cell death inhibits inflammation, apoptotic death of
infected cells, necrotic cell death, or factors released by stressed cells lead to
activation of different types of immune cells, including T and B lymphocytes,
macrophages (MF), and dendritic cells (DCs). The latter produce cytokines
that have either positive (red) or negative (blue) influences on cell survival
and proliferation and regulate different steps of tumorigenesis, including tumor
growth and progression. In addition, MF and DC may recruit other immune
cells into the tumormicroenvironment. Damaged or neighboring epithelial cells
can also release various cytokines, which further modulate cell survival and
growth.
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promotion (Figure 2).
It was shown that engulfment of apoptotic bodies by macro-
phages triggers the production of anti-inflammatory cytokines,
such as IL-10 (Savill et al., 2002). The universality of this concept,
however, has been challenged because apoptosis induced by
particular chemotherapeutic agents, such as anthracyclines
and ionizing radiation, was found to be inflammatory (Casares
et al., 2005; Fucikova et al., 2011). Mechanisms that allow
such agents to trigger inflammation include calreticulin translo-
cation (Obeid et al., 2007), heat shock protein 70 and 90 translo-
cation (Udono and Srivastava, 1994), and high mobility group
box 1 (HMG1) release (Apetoh et al., 2007). These events result
in dendritic cell (DC) and macrophage activation and a conse-quent inflammatory response (Zitvogel et al., 2010). In addition,
recognition of infected apoptotic cells at sites of infection-
induced injury culminates in enhanced production of IL-6, which
drives differentiation of proinflammatory T cells (Torchinsky
et al., 2009). Caspase 3-mediated cell death induced by therapy
results in the release of prostaglandins, which are known to
promote inflammation, but in this case directly promote the
survival of residual tumor cells (Huang et al., 2011).
Unlike apoptosis, necrosis or pyroptosis (defined as cell death
that is dependent on inflammatory caspase-1 activity) involve
rupture of the plasma membrane and release of the cell’s
content, making these mechanisms of cell death naturally
inflammatory (Bortoluci and Medzhitov, 2010; Zitvogel et al.,
2010). Cellular components released during necrotic cell death
include IL-1a, ‘‘danger-associated molecular patterns’’ (DAMPs)
such as calreticulin, HMG-1, and S100A8 and 9 proteins (Ghir-
inghelli et al., 2009; Sakurai et al., 2008), and nucleotides and nu-
cleic acids such as ATP, RNA, and DNA, whose recognition
leads to DC and macrophage activation (Zitvogel et al., 2010).
Although early studies have shown that neutralization of HMG-
1 can block cell-death-induced inflammation (Scaffidi et al.,
2002), this is not universal and in many cases it has been rather
difficult to block the inflammation that follows tissue injury and
cancer cell death because of the release of a large number of
different inflammatory triggers. Pyroptotic cell death is depen-
dent on activation of caspases, which are also pivotal for the
processing and release of IL-1 and IL-18 (Bortoluci
and Medzhitov, 2010). For instance, IL-1a released by dying
hepatocytes in a liver challenged with the procarcinogen diethyl
nitrosamine (DEN) triggers IL-6 production, which activates
STAT3 and promotes liver regeneration and tumor growth (He
et al., 2010; Sakurai et al., 2008). Various environmental toxins
are also capable of triggering cell death-induced inflammation.
Components of tobacco smoke, asbestos, and silica particles
cause injury and cell death of the lung epithelium, thereby
establishing chronic inflammation (Dostert et al., 2008), which
promotes the growth of K-Ras-induced lung cancer (Takahashi
et al., 2010). Lipid accumulation makes hepatocytes within fatty
livers more prone to cell death upon exposure to hepatotoxic
stimuli (Tuncman et al., 2006) and the ensuing inflammatory
response, which involves TNF and IL-6 production, promotes
HCC development (Park et al., 2010).
One major factor that determines whether cell death is inflam-
matory is the rate and the extent of cell death. Slowly occurring
physiological cell death may provide phagocytes with enough
time to clear the resulting debris, but intense cell death during
tissue injury or after cancer therapy may exceed the clearance
capacity of tissue macrophages and, even when apoptotic in
origin, can trigger inflammation. Indeed, high doses of otherwise
noninflammatory genotoxic agents, such as cisplatin and UV
irradiation, can induce necrosis and consequent inflammation
(Caricchio et al., 2003; Dursun et al., 2006). Furthermore,
whereas cell death after androgen withdrawal in prostate cancer
is initially apoptotic (McKenzie and Kyprianou, 2006), androgen
withdrawal triggers an inflammatory response (Ammirante
et al., 2010). Most likely, extensive apoptosis results in secon-
dary necrosis (Zitvogel et al., 2010).
Recent data suggest the involvement of additional cell intrinsic
events in the release of cytokines during stress or injury. In thisImmunity 35, October 28, 2011 ª2011 Elsevier Inc. 469
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death or can be triggered by cell stress in the absence of death.
Oncogene activation (Mantovani et al., 2008), inactivation of
tumor suppressor p53 (Komarova et al., 2005) and cell senes-
cence induced by extensive DNA damage (Rodier et al., 2009)
can all lead to production of the tumor promoting cytokines
IL-1, IL-6, and IL-8. Often, stromal cells, such as fibroblasts,
sense alterations in tissue homeostasis, which precede injury
and tumor development and contribute to inflammation (Born-
stein et al., 2009; Stairs et al., 2011). Myofibroblast activation
in response to injury results in the production of numerous
inflammatory chemokines, including CXCL13, which lead to
B cell recruitment into androgen-deprived prostate tumors
(Ammirante et al., 2010). Undoubtedly, tissue injury and cell
death are important triggers of tumor promoting inflammation
(Figure 2).
Inflammation, Cytokine, Cell Death, and Survival
Paradoxically, the inflammatory cytokines that are produced in
response to cell death promote tumor development by
enhancing the survival of pre-malignant and fully malignant cells
(Grivennikov et al., 2010). The mechanisms that lead to the upre-
gulation of inflammatory cytokines in cancer, which can take
place both in autocrine and paracrine manners, are diverse
and their understanding is still rudimentary. We focus the
following discussion on the relationships between cell death,
cytokines and cell survival in the context of tissue injury and
tumor development.
In many cases, the better understood stimuli that link local
injury and cell death to inflammatory cytokine production under
cancerous conditions are pathogens or commensals that are
recognized by pattern recognition receptors (PRR) on immune
or epithelial cells (Medzhitov, 2007). Pathogens that establish
persistent infections, such as Helicobacter pylori or Hepatitis
B and C viruses (HBV; HCV) can lead to the chronic production
of pro-tumorigenic cytokines (Grivennikov et al., 2010). In addi-
tion to direct PRR activation, certain pathogens, for instance
hepatitis B virus (HBV) and hepatitis C virus (HCV), can trigger
cytokine production via induction of cell death. As mentioned
above, apoptotic cells typically induce expression of IL-10
and TGF-b (Savill et al., 2002), which suppress inflammation
and in some cases inhibit tumor development (Grivennikov
et al., 2010). However, recognition of infected apoptotic cells
results in upregulation of IL-6, which drives differentiation of
proinflammatory T helper IL-17-producing (Th17) cells (Torchin-
sky et al., 2009). Although this response is designed to promote
host defense followed by tissue repair, it can also stimulate
chronic inflammation and tumor growth, especially in cancers
that develop in mucosal surfaces and epithelial barriers popu-
lated by bacteria (Torchinsky et al., 2009; Wu et al., 2009). In
fact, a Th17-related cytokine signature was recently shown to
be a sign of bad prognosis in colorectal cancer (Tosolini
et al., 2011). In addition, components of the intestinal microflora
promote tumor development in Il10/ mice, which can be
prevented by antibiotic treatment (Chichlowski et al., 2008). As
discussed above, necrotic cell death caused by hypoxia, nutrient
or growth factor deprivation, or cancer therapy can lead to
sterile inflammation that, if recurrent, can promote tumor devel-
opment (Sakurai et al., 2008; Zitvogel et al., 2010).470 Immunity 35, October 28, 2011 ª2011 Elsevier Inc.Inflammatory cytokines are critical regulators of life versus
death decisions. IL-1 and IL-6 for instance are potent inducers
of cell survival and tumor development, through their ability to
activate prosurvival transcription factors, such as NF-kB and
STAT3. Other cytokines, such as Fas ligand (FasL) and TNF-
related apoptosis-inducing ligand (TRAIL), are potent activators
of caspase 8 and therefore are inducers of apoptotic cell death.
However, their close relative TNF has both prosurvival and pro-
death functions. Other cytokines can exert complex effects
on the tumor microenvironment that may affect cell survival
and death by more indirect means. According to the cancer
immunosurveillance theory (Dunn et al., 2004), death-inducing
cytokines (TRAIL, FasL, TWEAK, and occasionally TNF) and
cytokines that limit the proliferation of epithelial cells (type I inter-
feron [IFN] and TGF-b) may constitute an important anticancer
defense system. This system can eliminate transformed cells
and kill metastatic seeds (Swann and Smyth, 2007). Naturally,
such cytokines were considered as cancer treatments, but so
far success has been rather limited. Nonetheless, genetic or
pharmacological blockade of death cytokines often (but not
always) increases susceptibility of mice to spontaneous and
induced tumorigenesis (Swann and Smyth, 2007). For example,
mice lacking membrane-bound forms of FasL or TRAIL develop
sarcomas and various blood cancers (Smyth et al., 2003; Swann
and Smyth, 2007). TRAIL, in combination with retinoic acid deriv-
atives (required to upregulate TRAIL receptors on cancer cells),
can kill tumors by apoptosis and limit growth of microadenomas
in ApcMin mice (Zhang et al., 2010a). Transgenic mice, which
overexpress TRAIL in the skin, exhibit reduced tumorigenicity
in the two-step model of skin carcinogenesis (Kedinger et al.,
2011). Inhibition of NF-kB activation by TNF, which acts as a pro-
survival cytokine, renders metastatic colon cancer cells suscep-
tible to the cytocidal action of TRAIL (Luo et al., 2004). Cytokines
such as IFN-g and IL-12 rarely kill cancer cells directly, but are
required for activation of immunosurveillance, including natural
killer (NK) cells and cytotoxic T cells (Dunn et al., 2004). Mice
deficient in components of IFN-g signaling are susceptible to
induction of sarcomas by methylcholanthrene and other malig-
nancies, including colitis-associated cancer, and also demon-
strate increased rates of experimental metastasis (Shankaran
et al., 2001; Swann and Smyth, 2007). However, mice lacking
both IFN-g and granulocyte macrophage-colony stimulating
factor (GM-CSF) exhibit inflammation and spontaneous devel-
opment of lymphomas and solid tumors due to chronic bacterial
infections (Enzler et al., 2003). Type I IFNs exhibit multifaceted
antitumorigenic effects via several distinct mechanisms. First,
they restrain proliferation or induce death of premalignant cells,
regardless whether such cells are infected with oncogenic
viruses or not. Second, type I IFNs upregulate expression of
stress-induced surface molecules, such as ligands for gdT cells
and NK cells, as well as major histocompatibility complex (MHC)
class I molecules, subjecting IFN-exposed cancer cells to
enhanced immunosurveillance (Dunn et al., 2005). A third and
largely unexplored mechanism of type I IFN action lies in their
ability to suppress inflammation, particularly tumor -associated
inflammation.
TNF, as its name indicates, was discovered as a death cyto-
kine that induces lysis of sarcoma cells (Carswell et al., 1975).
Binding of TNF to its type I receptor (TNFR1) can lead to caspase
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protein (RIP) 3 activation, which can lead to necrosis (Kaiser
et al., 2011; Oberst et al., 2011). In addition, TNFR1 engagement
leads to IkB kinase (IKK) and NF-kB activation, which inhibit
apoptosis, as well as c-jun N-terminal kinase (JNK) activation,
which can potentiate both forms of cell death and stimulate
production of ROS (Chang et al., 2006; Ventura et al., 2004).
TNF can induce the regression of certain tumors when adminis-
tered at high doses, most likely through the killing of endothelial
cells and thereby starving the tumors of blood supply (Balkwill,
2009). However, there is also ample evidence that TNF is a potent
tumor promoter (Balkwill, 2009). Importantly, TNF can directly
activate prosurvival NF-kB signaling in cancer cells, as demon-
strated in a model of inflammation-dependent cholestatic liver
cancer (Pikarsky et al., 2004). A similar effect has been demon-
strated for the TNF-related cytokine lymphotoxin (LT), whose
overexpression in liver leads to development of HCC in amanner
dependent on IKKb signaling (Haybaeck et al., 2009). TNF can
also stimulate the proliferation of premalignant cells, most likely
through its ability to activate AP-1 transcription factors (Balkwill,
2009). In addition, TNF has a potent protumorigenic effect in
ovarian and colitis-associated cancer, via indirect effects on
immune and stromal cells in the microenvironment (Charles
et al., 2009; Popivanova et al., 2008). A protumorigenic effect
has also been demonstrated for the TNF family member BAFF,
whose overexpression in Em-Myc transgenic mice leads to rapid
development of chronic lymphocytic leukemia (Zhang et al.,
2010b). Thus, the protumorigenic effect of antiapoptotic cyto-
kines is not limited to solid malignancies and is also observed
in tumors of hematopoietic origin.
Another well-established protumorigenic cytokine is IL-6
(Naugler and Karin, 2008). IL-6 exerts its protumorigenic activ-
ities by enhancing the survival and proliferation of premalignant
cells, as first demonstrated in colitis associated cancer (Becker
et al., 2004; Bollrath et al., 2009; Grivennikov et al., 2009). Most
of the pro-tumorigenic effects of IL-6 depend on activation of
STAT3, a transcription factor found to be activated in many
cancers, including those of the colon, stomach, breast and
prostate (Yu et al., 2009). STAT3 exerts its pro-survival and
anti-apoptotic activities through transcriptional activation of
classical pro-survival genes, such as Bcl-XL, as well as genes
involved in maintenance of epithelial sheet integrity and antimi-
crobial immunity such as Hsp70 and RegIII (Bollrath et al.,
2009). Loss of barrier integrity as demonstrated by the deletion
of p120-catenin, an adhesion protein whose expression is
downregulated in human gastric cancer, can result in epithelial
cell death and formation of a protumorigenic and inflam-
matory microenvironment (Stairs et al., 2011). Similar effects
have been observed during the development of pancreatic
cancer (Fukuda et al., 2011; Lesina et al., 2011). The exact
mechanisms by which loss of adhesion proteins results in cell
death are not entirely clear, but it is tantalizing to speculate
that diminished cell adhesion can lead to cell death by anoikis,
a type of cell death caused by the loss of cell to cell contact. In
summary, cytokines produced in response to injury and cell
death have a profound effect on cell death versus survival deci-
sions, thereby contributing to tumor initiation, growth, progres-
sion, and metastasis, as well as to the response to antitumor
therapy.Liver Cancer—A Death-Driven Cancer
Two important hallmarks of cancer are uncontrolled cell prolifer-
ation and the ability to avoid programmed cell death (Hanahan
and Weinberg, 2000). Accordingly, apoptotic cell death is
believed to be a major tumor-suppressive mechanism. Indeed,
many of the examples outlined above support this concept.
However, tumor suppression by apoptosis is not universal and
several cancers, especially liver cancer, are caused by cell
death. For induction of neoplasia, oncogenic mutations or epige-
netic modifications need to be fixed within subsequent cell
generations and therefore genetically altered cells have to divide
before giving rise to cancer (Figure 3). Although this is not amajor
obstacle in rapidly renewing epithelia, many tissues, such as the
liver, exhibit very low rates of cell proliferation. In fact, adult liver
parenchymal cells are synchronized at the G0 phase of the cell
cycle and can be evoked to proliferate only in response to tissue
damage or debulking (Luedde and Schwabe, 2011). Not surpris-
ingly, HCC, themajor form of adult liver cancer, almost invariably
develops in the context of chronic liver inflammation linked
to injury and cell death and caused by infection with HBV or
HCV, chronic alcohol consumption, excessive hepatosteatosis,
or exposure to environmental toxins (El-Serag and Rudolph,
2007). Initially, it was assumed that NF-kB activation may
promote the development of chemically induced HCC by sup-
pressing p53-induced apoptosis, as found in tissue culture
studies (Tergaonkar et al., 2002). We were therefore surprised
to find that inactivation of liver NF-kB through the cell type-
specific ablation of IKKb leads to amarked enhancement of hep-
atocarcinogenesis in DEN-treated mice (Maeda et al., 2005).
Similar observations were made in mice with a hepatocyte-
specific deletion of the stress-activated protein kinase p38a
(Hui et al., 2007; Sakurai et al., 2008). IKKb-mediated NF-kB
and p38a-regulated Hsp25 expression are critical for prevention
of excessive ROS accumulation and thus are important for the
survival of pericentral hepatocytes that are engaged in DEN
metabolism (Maeda et al., 2005; Sakurai et al., 2008). Thus, in
the absence of either NF-kBor p38a, DEN-exposed hepatocytes
undergo excessive cell death, resulting in an enhanced regener-
ative response and compensatory proliferation of surviving
hepatocytes. We have therefore proposed that enhanced
compensatory proliferation is the major cause of augmented
HCC development in both IKKb- and p38a-hepatocyte-specific
knockout mice (Karin, 2006). The regenerative response that
leads to compensatory hepatocyte proliferation depends on
the release of IL-1a by dying hepatocytes and the activation of
the adaptor MyD88-dependent IL-1R signaling in resident liver
macrophages (Kupffer cells), leading to IL-6 production by the
latter (Naugler et al., 2007; Sakurai et al., 2008). Strikingly, hepa-
tocyte-specific deletion of IKKg (NEMO), the regulatory subunit
of the IKK complex (Luedde et al., 2007) or TAK1, an upstream
kinase required for NF-kB activation (Bettermann et al., 2010; In-
okuchi et al., 2010), result in spontaneous liver damage, inflam-
mation, and hepatosteatosis, which eventually lead to HCC
development in the absence of any exogenous carcinogen. Curi-
ously, tumor development in the absence of TAK1 is reported to
be NEMO dependent and TAK1 can gain protumorigenic activity
in the absence of NEMO, underscoring their potential role as
both tumor promoters and tumor suppressors (Bettermann
et al., 2010). These opposing activities of TAK1 and NEMO areImmunity 35, October 28, 2011 ª2011 Elsevier Inc. 471
Figure 3. Protumorigenic Function of Cell
Death and Tissue Injury
Sentinel immune cells are present in normal tissue,
but they do not produce inflammatory cytokines
and do not promote tumorigenesis. As shown in
(A), inflammation results in immune cell infiltration,
but without extensive tissue injury and cell death,
tumor promotion typically does not take place,
although mutant cells can already be present.
Tissue injury and cell death induce additional
inflammation, which precedes or accompanies
tumor development. Tissue injury and cell death,
in combination with inflammation, result in an
enhanced regenerative response, leading to the
proliferation of stem cells that may harbor onco-
genic mutations. Immune cells, in turn, maintain
chronic inflammation and may cause additional
tissue injury. This altogether leads to tumor initia-
tion, promotion, and further enhancement of
tumor progression andmetastasis andmodulation
of antitumor therapy response by inflammation. As
shown in (B), inflammation can regulate tumor
promotion, progression, and metastasis by other
mechanisms, which do not invoke tissue damage
and cell death. These mechanisms are present
in established tumors and rely on late recruitment
of immune cells to the tumor microenviron-
ment as a part of tumor-elicited inflammation.
Factors produced by cancer cells, environmental
factors, and cell stress and death caused by
therapy and/or by hypoxia are responsible for cell
recruitment and tumor-associated inflammation in
this case.
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other transcription factors, such as AP-1 and SMADs.
Consistent with the protumorigenic function of hepatocyte
death, mice that are specifically devoid of the death receptor
Fas on hepatocytes exhibit a substantial decrease in DEN-
induced hepatocarcinogenesis (Chen et al., 2010). So that one
could fully appreciate the importance of these findings, it should
be noted that in many other cell types, especially in lymphocytes
and their precursors, Fas has been shown to act as a tumor
suppressor (Peter et al., 2007). It should also be noted that
administration of DEN to mice that are older than one month of
age does not lead to HCC induction, unless combined with
a tumor promoter, such as phenobarbital or carbon tetrachloride
(CCl4) (Maeda et al., 2005). Congruently, feeding of mice with
a high fat diet (HFD) for 3 months prior to DEN administration
greatly enhanced DEN-induced ROS accumulation and hepato-472 Immunity 35, October 28, 2011 ª2011 Elsevier Inc.cyte death, resulting in HCC induction in
the absence of other tumor promoters
(Park et al., 2010). In addition to
enhancing DEN-induced liver damage,
consumption of HFD results in elevated
expression of TNF and IL-6, both of which
promote HCC development (Park et al.,
2010). Paradoxically, while inducing
hepatocyte proliferation, IL-6 also poten-
tiates DEN-induced hepatocyte death
(Naugler et al., 2007). The latter effect
may be due to IL-6-induced neutrophil
recruitment. Such observations may
also explain why hepatocyte-specificStat3 null mice are protected from DEN-induced HCC (He
et al., 2010), but are highly susceptible to HCC induction upon
challenge with CCl4, a liver-damaging agent that does not cause
HCC by itself (Wang et al., 2011). A number of retrospective
studies suggest that IL-6 is also involved in the pathogenesis
of human HCC and inflammatory liver adenomas (Naugler and
Karin, 2008; Rebouissou et al., 2009).
As mentioned above, NF-kB signaling has a dual role in
hepatocarcinogenesis. While enhancing DEN-induced HCC
development, inhibition of liver NF-kB activity can attenuate
inflammation-induced HCC that is not accompanied by obvious
liver injury (Haybaeck et al., 2009; Pikarsky et al., 2004). Indeed,
there is substantial heterogeneity in respect to NF- kB activation
in human HCC. Although the majority of HCCs appear to be
devoid of nuclear RelA, (a subunit of the NF-kB multiprotein
complex) 25% of such tumors exhibit clear NF-kB activation,
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Reviewsuggesting that even in human liver, NF-kB can assume
both antitumorigenic and protumorigenic functions (He et al.,
2010).
Cell Death and Skin Cancer
Death-promoted tumorigenesis is not unique to the liver as injury
can play both tumor-suppressive and tumor-promoting effects
in the skin. Squamous cell carcinoma (SCC) and basal cell carci-
noma (BCC) are the most prominent nonmelanoma forms of skin
cancer and two of the most common cancers worldwide
(Domingo and Baron, 2008). Inflammatory processes are impor-
tant for induction, promotion, and progression of both SCC and
BCC. However, given that the incidence of these cancers is
higher in immunocompromised individuals, the immune system
and inflammation may have dual roles in skin carcinogenesis.
Death promoting environmental challenges, including UV irradi-
ation, tobacco smoke, and betel nut chewing are major contrib-
utors to the etiology of SCC (Rudolph and Zelac, 2004). The skin
consists of different cell types and serves as a critical barrier
that protects us from microbes, harmful chemicals, and dehy-
dration. Skin integrity is maintained by the ongoing division of
stem cells and transient amplifying cells in its basal layer, which
give rise to more differentiated cell types that eventually undergo
enucleation to form the cornified cell bodies that make up the
outermost layer.
As in the liver, chronic stress and injury, as well as defects in
normal wound healing, can cause skin cancer (Rudolph and
Zelac, 2004). For instance, repetitive exposure to UV radiation
causes skin injury and cell death and leads to tumor develop-
ment. Although UV radiation is a potent DNA damaging agent
and a mutagen, not all of its effects depend on DNA damage.
The TGF-b-SMAD4 signaling pathway is required for efficient
epithelial wound healing and a conditional deletion of SMAD4
in the epidermis results in severe defects in skin wound healing
that are accompanied by spontaneous skin lesions, inflamma-
tion, and SCC (Owens et al., 2010). Likewise and as seen in
the liver, inhibition of epidermal NF-kB activation results in
enhanced skin tumorigenesis (Dajee et al., 2003). However, abla-
tion of the NF-kB activating cytokine TNF inhibits two-stage skin
cancer carcinogenesis (Moore et al., 1999). As discussed above,
TNF is likely to exert its protumorigenic activity through the tran-
scription factor AP-1, as ablation of the transcription factor c-Jun
inhibits skin tumorigenesis (Schonthaler et al., 2011). However,
ablation of both c-Jun and JunB results in psoriatic inflammation
(Schonthaler et al., 2011). Notably, despite being a chronic
inflammatory condition linked to increased production of TNF,
psoriasis is associated with protection from skin tumorigenesis
(Nickoloff et al., 2005), presumably because psoriasis does not
cause excessive tissue injury and cell death (see below). Another
transcription factor involved in psoriasis is STAT3, which can be
activated by a large variety of cytokines, including EGF, HB-EGF,
IL-22, and IL-6, which can be particularly induced by stresses
and cell injury. STAT3 integrates prosurvival signals from these
cytokines and its ablation in the epidermis inhibits two-stage
skin carcinogenesis (Kataoka et al., 2008).
Skin damage can result in the release of self-antigens and
DAMPs, leading to activation of innate and adaptive immunity
and stimulation of T and B cells responses (de Visser et al.,
2005). In K14-HPV16 transgenic mice, which overexpresshuman papilloma virus (HPV) 16 proteins E6 and E7 in keratino-
cytes and spontaneously develop skin papillomas, antibody-
producing B cells lead to activation of mast cells via Fc
receptors, thereby triggering a local inflammatory response
that stimulates tumor progression (Andreu et al., 2010; de Visser
et al., 2005). In a two-step skin carcinogenesis model, B cells
producing IL-10 promote papilloma growth by inactivating anti-
tumor immunity represented by cytotoxic T cells and the antitu-
morigenic cytokine IFN-g (Schioppa et al., 2011). The DAMPs
HMG-B1 and B2 are upregulated during SCC progression and
may be required for establishment of chronic inflammation,
cancer invasion, and metastasis (Sharma et al., 2008). The iden-
tity of the antigens that activate the adaptive immune response in
skin injury and cancer remains unknown, although self-antigens,
such as chitinase-like proteins (Qureshi et al., 2011) and antigens
derived from the skin bacterium Staphylococcus aureus (Daniel
et al., 2003), have been implicated. T cell responses play a
dual role in skin tumorigenesis. Whereas IL-12- and IFN-g-driven
cytotoxic T cells inhibit initiation and progression of skin cancer,
IL-23- and IL-17-mediated responses promote skin tumorigen-
esis (Langowski et al., 2006).
As mentioned above, certain types of chronic skin inflamma-
tion, such as psoriasis or atopic dermatitis, do not increase the
risk of skin cancer development. It is tempting to speculate
that they fail to do so because no prominent tissue damage
and subsequent regeneration are inflicted under these condi-
tions. It is also plausible that chronic injury also increases
the exposure of normal cells to environmental mutagens and
carcinogens, which are normally kept at bay by the skin’s barrier
function. Given the physiology and anatomy of the epidermis,
which consists of stem cells, rapidly dividing basal cells and
differentiated cells, which eventually undergo enucleation and
death, a key question is when and not whether these keratino-
cytes will eventually die. Therefore, keratinocyte death is
probably not a major suppressor of skin tumorigenesis. Rather,
the continuous death of differentiated keratinocytes results in
expansion of transient amplifying cells, some of which may
harbor oncogenic mutations, thereby promoting tumorigenesis.
Thus, unless cell death is restricted to transformed cells
harboring oncogenic mutations, it is not universally tumor
suppressive. In the case of melanoma, tumor development
does not seem to depend on earlier tissue injury and cell death
while tumor-cell specific NF-kB activation promotes tumorigen-
esis (Yang et al., 2010). On the other hand, activation of melano-
cyte precursors by UVB light, a typical stress stimulus, and
IFN-g, promotes the recruitment of immune cells and enhances
melanoma development in an animal model (Zaidi et al., 2011).
Here, IFN-g provides prosurvival and protumorigenic signals to
initiated melanocytes.
Concluding Remarks
Chronic tissue damage and inflammation have long been sus-
pected for their ability to promote cancer development and
progression, but only recently was the incriminating ‘‘smoking
gun’’ identified through the extensive use of physiologically
relevant mouse models. Importantly, the experimental evidence
obtained in mice is strongly supported by correlative and retro-
spective analysis of human clinical and epidemiological data.
One of the earliest experiments that underscored the importanceImmunity 35, October 28, 2011 ª2011 Elsevier Inc. 473
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Reviewof tissue injury and cell death in tumorigenesis was the demon-
stration that v-Src oncogene cannot induce cancer unless
accompanied by tissue injury and subsequent regeneration (Sie-
weke et al., 1990). Likewise, experimental pancreatic injury is
required to unravel the oncogenic potential of activated K-Ras
in the postnatal pancreas (Guerra et al., 2007). In lung cancer,
tissue injury inflicted by tobacco smoke contributes to disease
development, and inhibition of cell death related pathways
(JNK) or death-induced proinflammatory cytokines (TNF and
IL-6) dampens tumor progression (Takahashi et al., 2010).
Disruption of epithelial homeostasis by deletion of p120 catenin
induces esophageal cancer (Stairs et al., 2011). An inflammatory
bowel disease, such as ulcerative colitis (UC), which is charac-
terized bymassive epithelial damage and inflammation, is known
to elevate colon cancer risk (Saleh and Trinchieri, 2011). Like-
wise, mucosal injury induced by dextrane sulfate sodium (DSS)
or by oxazolone is required for induction of colitis-associated
cancer in mice treated with the procarcinogen azoxymethane
(AOM) (Greten et al., 2004; Schiechl et al., 2011). Taken together,
these and many other experiments illustrate the protumorigenic
activity of cell death and together with clinical and epidemiolog-
ical findings support the notion that a substantial fraction of all
cancer cases are likely to be initiated and promoted by chronic
tissue injury (Figure 3). These conclusions also suggest that ther-
apeutic approaches that minimize injury and restore normal
tissue homeostasis can be used in cancer prevention.
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